297 related articles for article (PubMed ID: 22115405)
1. Modeling and predicting drug pharmacokinetics in patients with renal impairment.
Rowland Yeo K; Aarabi M; Jamei M; Rostami-Hodjegan A
Expert Rev Clin Pharmacol; 2011 Mar; 4(2):261-74. PubMed ID: 22115405
[TBL] [Abstract][Full Text] [Related]
2. Emerging evidence of the impact of kidney disease on drug metabolism and transport.
Nolin TD; Naud J; Leblond FA; Pichette V
Clin Pharmacol Ther; 2008 Jun; 83(6):898-903. PubMed ID: 18388866
[TBL] [Abstract][Full Text] [Related]
3. Consequences of renal insufficiency on the hepatic clearance of some drugs.
Balant LP; Dayer P; Fabre J
Int J Clin Pharmacol Res; 1983; 3(6):459-74. PubMed ID: 6147317
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications.
Zhang Y; Zhang L; Abraham S; Apparaju S; Wu TC; Strong JM; Xiao S; Atkinson AJ; Thummel KE; Leeder JS; Lee C; Burckart GJ; Lesko LJ; Huang SM
Clin Pharmacol Ther; 2009 Mar; 85(3):305-11. PubMed ID: 19020495
[TBL] [Abstract][Full Text] [Related]
5. Regulatory perspectives on designing pharmacokinetic studies and optimizing labeling recommendations for patients with chronic kidney disease.
Zhang L; Xu N; Xiao S; Arya V; Zhao P; Lesko LJ; Huang SM
J Clin Pharmacol; 2012 Jan; 52(1 Suppl):79S-90S. PubMed ID: 22232757
[TBL] [Abstract][Full Text] [Related]
6. Altered disposition of drugs in acute renal failure rat models: drug development strategies and perspectives.
Srinivas NR
Arzneimittelforschung; 2010; 60(12):731-48. PubMed ID: 21265465
[TBL] [Abstract][Full Text] [Related]
7. Renal disease and drug metabolism: an overview.
Gibson TP
Am J Kidney Dis; 1986 Jul; 8(1):7-17. PubMed ID: 3524205
[TBL] [Abstract][Full Text] [Related]
8. Effects of renal failure on drug transport and metabolism.
Sun H; Frassetto L; Benet LZ
Pharmacol Ther; 2006 Jan; 109(1-2):1-11. PubMed ID: 16085315
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a novel method to estimate absolute bioavailability of drugs from oral data.
Hinderling PH
Biopharm Drug Dispos; 2003 Jan; 24(1):1-16. PubMed ID: 12516074
[TBL] [Abstract][Full Text] [Related]
10. [Adjusting dosage of drugs in patients with kidney or liver failure].
Krähenbühl S
Schweiz Med Wochenschr; 1998 Feb; 128(6):189-94. PubMed ID: 9540139
[TBL] [Abstract][Full Text] [Related]
11. A new model-independent physiological approach to study hepatic drug clearance and its applications.
Chiou WL
Int J Clin Pharmacol Ther Toxicol; 1984 Nov; 22(11):577-90. PubMed ID: 6389376
[TBL] [Abstract][Full Text] [Related]
12. Development and application of physiologically based pharmacokinetic-modeling tools to support drug discovery.
Lüpfert C; Reichel A
Chem Biodivers; 2005 Nov; 2(11):1462-86. PubMed ID: 17191947
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study.
Lal R; Sukbuntherng J; Luo W; Chen D; Blumenthal R; Ho J; Cundy KC
Clin Ther; 2012 Jan; 34(1):201-13. PubMed ID: 22206794
[TBL] [Abstract][Full Text] [Related]
14. Effect of chronic renal failure on the disposition of highly hepatically metabolized drugs.
Yuan R; Venitz J
Int J Clin Pharmacol Ther; 2000 May; 38(5):245-53. PubMed ID: 10839468
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model.
Stoeckel K; Koup JR
Am J Med; 1984 Oct; 77(4C):26-32. PubMed ID: 6093514
[TBL] [Abstract][Full Text] [Related]
16. Understanding renal replacement therapy and dosing of drugs in pediatric patients with kidney disease.
Zuppa AF
J Clin Pharmacol; 2012 Jan; 52(1 Suppl):134S-40S. PubMed ID: 22232749
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
[TBL] [Abstract][Full Text] [Related]
18. When to conduct a renal impairment study during drug development: US Food and Drug Administration perspective.
Huang SM; Temple R; Xiao S; Zhang L; Lesko LJ
Clin Pharmacol Ther; 2009 Nov; 86(5):475-9. PubMed ID: 19844224
[TBL] [Abstract][Full Text] [Related]
19. A set of simple aids to drug dosage adjustment in renal insufficiency.
Janků I; Modr Z; Krebs V
Int J Clin Pharmacol Ther Toxicol; 1990 Jan; 28(1):27-32. PubMed ID: 2303310
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics in renal disease.
Levy G
Am J Med; 1977 Apr; 62(4):461-5. PubMed ID: 851113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
